SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that it will host a panel discussion in San Francisco, on Monday, November 7, 2011 to review and discuss the Promacta Phase III ENABLE 1 study results. The ENABLE 1 data will be presented earlier in the day during the Late-Breaking Abstract Session at the American Association for the Study of Liver Disease (AASLD) annual meeting.
